The effect of this peptide was even seen in combination treatment with cisplatin, suggesting an in vivo sensitization of ovarian cancer cells to cisplatin by inhibiting BRCA1- IRIS survival pathways (Figure 1) [3]. This evidence concerns the gene BRCA1 and ovarian carcinoma.